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Abstract
Background: Sarilumab is a human monoclonal antibody directed against the alpha subunit of the interleukin-6
receptor complex. In the MOBILITY phase III randomized controlled trial (RCT), sarilumab +methotrexate (MTX)
treatment resulted in clinical improvements at 24 weeks that were maintained at 52 weeks in adults with
rheumatoid arthritis (RA), who have inadequate response to MTX (MTX-IR). These analyses indicate the effects of
sarilumab + MTX versus placebo on patient-reported outcomes (PROs) in this RCT.
Methods: Patients (n = 1197) were randomized to receive placebo, sarilumab 150 or 200 mg subcutaneously + MTX
every 2 weeks for 52 weeks; after 16 weeks, patients without ≥20 % improvement from baseline in swollen or
tender joint counts on two consecutive assessments were offered open-label treatment. PROs included patient
global assessment of disease activity (PtGA), pain, health assessment questionnaire disability index (HAQ-DI), Short
Form-36 Health Survey (SF-36), and functional assessment of chronic illness therapy-fatigue (FACIT-F). Changes from
baseline at weeks 24 and 52 were analyzed using a mixed model for repeated measures. Post hoc analyses
included percentages of patients reporting improvements equal to or greater than minimal clinically important
differences (MCID) and normative values in the FACIT-F and SF-36. Pearson correlation between observed PRO
scores and clinical measures of disease activity was tested at week 24.
Results: Both doses of sarilumab + MTX vs placebo + MTX resulted in improvement from baseline by week 24 in
PtGA, pain, HAQ-DI, SF-36 and FACIT-F scores (p < 0.0001) that was clinically meaningful, and persisted until week
52. In post hoc analyses, the percentages of patients with improvement equal to or greater than the MCID across
all PROs were greater with sarilumab than placebo (p < 0.05), with differences ranging from 11.6 to 26.2 %, as were
those reporting equal to or greater than normative scores.
Conclusions: In this RCT in patients with MTX-IR RA, sarilumab +MTX resulted in sustained improvement in PROs
that were clinically meaningful, greater than placebo + MTX, and complement the previously reported clinical
efficacy and safety of sarilumab.
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Background
The initial focus of most randomized controlled trials
(RCTs) of new therapeutic agents for rheumatoid arth-
ritis (RA) is appropriately directed at reducing the symp-
toms and signs of disease, demonstrating reduction in
the progression of structural damage, and improving
physical function and health-related quality-of life
(HRQOL). Crucial to the evaluation of a new therapeutic
agent is the use of patient-reported outcomes (PROs) to
comprehensively define treatment benefit as recom-
mended by current international consensus [1–3].
This manuscript reports PRO data from the 52-week
phase III MOBILITY RCT of sarilumab in combination
with methotrexate (MTX) in patients with RA, who have
inadequate response to MTX (MTX-IR) (clinicaltrials.
gov identifier NCT01061736) [4]. Sarilumab is a human
monoclonal antibody directed against the alpha subunit
of the interleukin-6 (IL-6) receptor complex, which me-
diates pathways that contribute to joint inflammation
and destruction, pain, and fatigue in RA [5, 6]. Clinical
improvements including symptomatic, functional, and
radiographic outcomes were observed at 24 weeks, as
early as 2 weeks in some outcomes, and were main-
tained over the 52-week study duration; the most
common treatment-emergent adverse events included
infection, neutropenia, injection site reaction, and in-
creased transaminase [4]. Current analyses evaluated the
impact of sarilumab on PROs, and correlation between
these and changes in disease activity.
Methods
Study design and population
The trial design and methods have been previously de-
scribed [4]; in short, patients were randomized to receive
subcutaneous placebo or sarilumab 150 mg or 200 mg
every 2 weeks (q2w) in combination with MTX. Treat-
ment duration was 52 weeks; on or after 16 weeks,
patients without ≥20 % improvement from baseline in
swollen or tender joint counts on two consecutive
assessments or any other lack of efficacy based on inves-
tigator judgment were offered rescue therapy with open-
label sarilumab 200 mg q2w. Efficacy was evaluated
using three co-primary efficacy endpoints: American
College of Rheumatology 20 % improvement (ACR20)
response [1] at week 24, physical function at week 16
using the health assessment questionnaire disability
index (HAQ-DI) [7], and change from baseline in radio-
graphic progression [8] at week 52.
Inclusion criteria were age 18–75 years; fulfilment of
ACR 1987 revised classification criteria for RA [9]; active
RA (swollen joint count ≥6, tender joint count ≥8; high
sensitivity C-reactive protein ≥0.6 mg/dl) despite stable
dosing with MTX for ≥12 weeks; anti-citrullinated pro-
tein antibodies (ACPA) or rheumatoid factor (RF) posi-
tivity or presence of one or more documented bone
erosions; or disease duration ≥3 months [4].
Patient-reported outcomes
The patient global assessment of disease activity (PtGA),
pain visual analog scale (VAS) and health assessment
questionnaire disability index (HAQ-DI) were adminis-
tered as part of the ACR response criteria [1] at baseline,
weeks 2 and 4, and every 4 weeks thereafter. Functional
assessment of chronic illness therapy-fatigue (FACIT-F)
[10] was administered at baseline, weeks 2, 4, 12, 24, 36,
and 52, and medical outcomes Short Form-36 (SF-36)
Health Survey version 2 [11] was administered at baseline,
and weeks 24 and 52 to evaluate general health status, also
described as HRQOL. The FACIT-F includes 13 items
rated by patients on a scale of 0–4 summarized as a total
score of 0–52, with higher scores indicating less fatigue.
The SF-36 evaluates eight domains (physical functioning
(PF), role physical (RP, i.e., limitations due to physical
health), body pain (BP), general health perceptions (GH),
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vitality (VT), social functioning (SF), role emotional (RF,
i.e., role limitations due to emotional health), and mental
health (MH)). For each domain, item scores are coded,
summed, and transformed on to a scale from 0 (worst
possible health state measured by the domain) to 100 (best
possible health state). These domains are combined into
physical component summary (PCS) and mental compo-
nent summary (MCS) scores with normative means (SD)
of 50 (10).
Statistical analyses
The intention-to-treat (ITT) population was used in the
current analyses. Changes from baseline at weeks 24 and
52 were analyzed using a mixed model for repeated mea-
sures (MMRM) that included treatment, prior biological
use, region, visit, and treatment by visit interaction as
fixed effects, and baseline score as a covariate; results
are expressed as least squares mean (LSM) and standard
error. In the MMRM analysis, for patients who required
rescue, only data up to the time of rescue were included.
Statistical significance was claimed only for those out-
comes above the break in hierarchical testing used to
control for multiple comparisons previously reported
[4]. All other p values were tested without adjustment
for multiplicity.
The proportion of patients reporting improvement
from baseline at week 24 equal to or greater than the
minimal clinically important difference (MCID) in
HAQ-DI scores was determined using thresholds ≥0.22
[12] and ≥0.3 points, with both thresholds prespecified.
Post hoc responder analyses were conducted to estimate
percentages of patients who reported improvement from
baseline equal to or greater than the MCID [12, 13] of
10 mm for PtGA and pain VAS scores [13–15]; 2.5
points for SF-36 PCS and MCS scores, 5 points for indi-
vidual domains [16]; and 4 points for the FACIT-F [10].
In these responder analyses, patients who discontinued
or received rescue medication were considered non-
Table 1 Baseline demographic and clinical characteristics of the intention-to-treat population
Variable Placebo +MTX (n = 398) Sarilumab 150 mg q2w +MTX (n = 400) Sarilumab 200 mg q2w +MTX (n = 399)
Age (years) 50.9 ± 11.2 50.1 ± 11.9 50.8 ± 11.8
Female (%) 80.7 79.8 84.5
Race (%)
Caucasian 86.2 86.3 86.0
Black 2.5 2.5 2.0
Asian 8.0 8.3 8.3
Other 3.3 3.0 3.8
Region (%)
Western Europe 18.6 18.8 18.8
South America 38.9 38.8 38.8
Rest of world 42.5 42.5 42.4
RA duration (years) 9.1 ± 8.1 9.5 ± 8.5 8.6 ± 7.0
Prior biologic DMARD use (%) 20.6 20.5 19.5
Seropositive for rheumatoid factor (%) 84.4 87.1 82.6
Anti-CCP antibody positive (%) 85.4 90.2 84.9
Tender joint count 26.8 ± 13.8 27.2 ± 14.2 26.5 ± 14.5
Swollen joint count 16.7 ± 9.3 16.6 ± 9.0 16.8 ± 9.7
CRP (mg/dl) 2.0 ± 2.3 2.4 ± 2.3 2.2 ± 2.4
DAS28-CRP 5.9 ± 0.9 6.0 ± 0.9 6.0 ± 0.9
PtGA (VAS) 63.7 ± 19.9 64.4 ± 20.4 66.3 ± 20.8
Pain VAS 63.7 ± 19.9 65.4 ± 21.4 66.7 ± 21.4
HAQ-DI 1.6 ± 0.7 1.6 ± 0.6 1.7 ± 0.6
FACIT-F 27.2 ± 10.4 26.3 ± 9.8 25.9 ± 10.4
SF-36 PCS 31.9 ± 6.9 31.5 ± 6.7 31.1 ± 6.8
SF-36 MCS 38.9 ± 11.4 39.0 ± 11.3 38.7 ± 12.0
Numbers are presented as mean ± SD unless mentioned otherwise. q2w every 2 weeks, MTX methotrexate, Anti-CCP anti-cyclic citrullinated peptide, CRP C-reactive
protein, DAS28-CRP 28-joint disease activity score using C-reactive protein, DMARD disease-modifying anti-rheumatic drug, FACIT-F functional assessment of
chronic illness therapy-fatigue scale, HAQ-DI health assessment questionnaire disability index, SF-36 36-item Short Form Health Survey-Version 2, MCS mental
component summary, PCS physical component summary, PtGA patient global assessment of disease activity, RA rheumatoid arthritis, VAS visual analog scale
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responders. The number-needed-to-treat (NNT) was
calculated as the reciprocal of the difference in response
rates between active treatment and placebo to obtain the
outcome of interest in one patient, assessing the magni-
tude of the benefit obtained with treatment [17]. To
further assess benefit, the proportion of patients who re-
ported normative values in the SF-36 summary and do-
main scores and the FACIT-F were evaluated at week 24,
as were those who reported values equal to or greater than
the patient acceptable symptom state (PASS) thresholds in
the six SF-36 domains for which it has been estimated (PF,
50; BP, 41; GH, 47; VT, 40; SF, 62.5; and MH, 72) [18].
The percentage of ACR20 responders who reported im-
provements equal to or greater than the MCID was deter-
mined post hoc. Correlation analysis (Pearson r) was
performed to determine relationships between individual
PROs and clinical measures of disease activity including
28-joint disease activity score using C-reactive protein
(DAS28-CRP) and the clinical disease activity index
(CDAI) at week 24. All analyses were performed using
SAS version 9.2 (SAS Institute, Cary, SC, USA).
Results
Demographic and disease characteristics
Baseline characteristics were balanced across treatment
groups (Table 1). Duration of RA ranged from 8.6 to
9.5 years and approximately 20 % of patients had previ-
ously received biologic disease-modifying anti-rheumatic
drugs (DMARDs).
Changes from baseline
LSM improvements from baseline at week 24 in the
PtGA, pain, and HAQ-DI scores were greater with sari-
lumab 150 mg and 200 mg than placebo (p < 0.0001)
and were maintained at week 52 (Table 2). The FACIT-F
demonstrated improvement at week 24 with sarilumab
150 mg and 200 mg that was significantly greater than
placebo and was maintained through week 52 (p <
0.0001 for both doses at both time points) (Table 2). Sig-
nificant improvements were reported in the SF-36 PCS
and MCS scores at week 24 with sarilumab compared
with placebo (p < 0.05). Greater improvements were also
observed with sarilumab in all eight domains at week 24
and at week 52 (p < 0.05) with the exception of the MCS
and RE scores with sarilumab 150 mg at week 52
(Table 2). Improvements in PtGA, pain, HAQ-DI, and
FACIT-F scores were evident by 2 weeks after the start
of treatment (Fig. 1).
As shown in Fig. 2, the SF-36 mean baseline domain
scores were approximately 20 to 50 points lower than an
age-matched and gender-matched normative US popula-
tion, as a benchmark comparison, indicating substantial
Table 2 Change from baseline in patient-reported outcome scores at weeks 24 and 52
Patient-reported
outcome
(n) Least square mean ± standard error




q2w +MTX (n = 400)
Sarilumab 200 mg




q2w +MTX (n = 400)
Sarilumab 200 mg
q2w +MTX (n = 399)
PtGA (253) -15.7 ± 1.4 (312) -28.3 ± 1.3*** (319) -32.9 ± 1.3*** (196) -20.3 ± 1.5 (272) -31.7 ± 1.4*** (272) -32.8 ± 1.4***
Pain VAS (253) -15.4 ± 1.4 (313) -28.5 ± 1.4*** (321) -31.8 ± 1.3*** (196) -19.3 ± 1.6 (273) -32.7 ± 1.4*** (272) -33.1 ± 1.4***
HAQ-DI (253) -0.32 ± 0.03 (313) -0.56 ± 0.03*** (316) -0.57 ± 0.03*** (195) -0.27 ± 0.04 (272) -0.62 ± 0.03*** (270) -0.63 ± 0.03***
FACIT-F (252) 5.8 ± 0.5 (311) 8.6 ± 0.5*** (320) 9.2 ± 0.5*** (195) 6.1 ± 0.5 (270) 9.1 ± 0.5*** (271) 9.2 ± 0.5***
SF-36 component scores
PCS (246) 5.2 ± 0.5 (299) 8.0 ± 0.5*** (309) 8.4 ± 0.5*** (187) 5.6 ± 0.6 (257) 9.2 ± 0.5*** (263) 9.1 ± 0.5***
MCS (246) 3.9 ± 0.6 (299) 5.7 ± 0.6* (309) 8.2 ± 0.6*** (187) 5.5 ± 0.7 (257) 7.1 ± 0.6 (263) 8.4 ± 0.6**
SF-36 domain scores
Physical functioning (253) 11.9 ± 1.5 (312) 17.5 ± 1.3* (316) 18.2 ± 1.3** (195) 13.9 ± 1.6 (272) 21.3 ± 1.4** (269) 21.3 ± 1.4**
Role physical (252) 12.8 ± 1.4 (309) 18.7 ± 1.3** (318) 20.4 ± 1.3*** (194) 15.5 ± 1.5 (266) 20.7 ± 1.3* (271) 22.5 ± 1.3**
Body pain (250) 15.3 ± 1.3 (312) 25.3 ± 1.2*** (318) 27.6 ± 1.2*** (192) 16.7 ± 1.5 (272) 28.1 ± 1.3*** (269) 28.0 ± 1.3***
General health (248) 7.6 ± 1.1 (307) 12.80 ± 1.0** (319) 15.2 ± 1.0*** (191) 10.5 ± 1.3 (269) 14.5 ± 1.1* (271) 15.9 ± 1.1**
Vitality (251) 9.8 ± 1.2 (308) 13.9 ± 1.1* (320) 18.0 ± 1.0*** (194) 11.4 ± 1.3 (268) 17.5 ± 1.1** (271) 17.7 ± 1.1**
Social functioning (252) 9.8 ± 1.4 (312) 17.3 ± 1.2*** (320) 20.8 ± 1.2*** (195) 11.9 ± 1.6 (272) 20.4 ± 1.4*** (271) 20.8 ± 1.4***
Role emotional (252) 10.3 ± 1.5 (308) 14.6 ± 1.4* (318) 17.9 ± 1.4*** (193) 14.8 ± 1.6 (264) 17.3 ± 1.4 (269) 21.4 ± 1.4*
Mental health (251) 7.4 ± 1.1 (308) 10.4 ± 1.0* (320) 14.0 ± 1.0*** (194) 9.8 ± 1.2 (268) 13.0 ± 1.1* (271) 14.3 ± 1.1*
q2w every 2 weeks, FACIT-F functional assessment of chronic illness therapy-fatigue scale, HAQ-DI health assessment questionnaire disability index, SF-36 36-item
Short Form Health Survey-Version 2, MCS mental component summary, MTX methotrexate, PCS physical component summary, PtGA patient global assessment of
disease activity, VAS visual analog scale. *p < 0.05, **p < 0.001, and ***p < 0.0001 versus placebo +MTX
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Placebo + MTX Sarilumab 150 mg q2w + MTX Sarilumab 200 mg q2w  + MTX
Fig. 1 Mean scores at each visit through week 24 for a patient’s global assessment of disease activity, b pain, c physical function, and d fatigue.
Broken vertical line indicates the earliest opportunity for rescue medication; patients who did not achieve ≥20 % improvement from baseline in
swollen or tender joint count on two consecutive assessments were offered rescue therapy with open-label sarilumab 200 mg every 2 weeks.
HAQ-DI health assessment, FACIT-F functional assessment of chronic illness therapy-fatigue questionnaire disability index, MTX methotrexate
Fig. 2 Combined baseline (BL) and post-treatment scores at week 24 across all Short Form 36 (SF-36) domains relative to age-adjusted and
gender-adjusted norms (A/G matched norms) for the US general population. All scores on a 0–100 scale (0 = worst, 100 = best). PF physical
functioning, RP role physical, BP body pain, GH general health, VT vitality, SF social functioning, RE role emotional, MH mental health. Note, as
combined baseline scores are presented, change from baseline for each cohort cannot be inferred from Fig. 2 alone
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impairment of general health status. At week 24, pa-
tients receiving both sarilumab doses reported greater
improvement from baseline versus placebo across all
eight domains (p < 0.05), and VT scores approached
normative values.
Responder analyses
In post hoc analyses, the percentages of patients report-
ing improvement equal to or greater than the MCID
were higher with both doses of sarilumab than placebo
across all PROs (p < 0.05), resulting in a NNT ranging
from 4.0 (PCS for sarilumab 200 mg) to 8.6 (MCS for
sarilumab 150 mg) (Fig. 3a). The percentage of patients
who reported improvement equal to or greater than the
MCID in individual SF-36 domains was consistently
higher with both doses of sarilumab versus placebo for
all domains (p < 0.05) (Fig. 3b); the NNT ranged from
3.8 (BP with the sarilumab 200 mg dose) to 9.7 (MH
with the sarilumab 150 mg dose). The majority (59.4–
89.8 %) of ACR20 responders reported clinically mean-
ingful improvement across PROs.
The percentage of patients reporting scores equal to or
greater than normative values in the FACIT-F and SF-36
domains was low across treatment groups at baseline, ran-
ging from 1.9 % for BP to 21.4 % for VT (Fig. 4a), although
higher proportions reported values exceeding PASS
thresholds (from 15 % for BP to 48 % for VT) (Fig. 4b). At
week 24, the percentage of patients who reported scores
equal to or greater than normative values across the
FACIT-F and SF-36 domains was greater with sarilumab
treatment in the individual domains of BP, GH, SF, and
MH domains with 150 mg, and across all domains with
200 mg except PF (p < 0.05) (Fig. 4c). The percentage of
patients reporting scores equal to or greater than PASS
was also higher with both doses of sarilumab relative to
placebo (p < 0.05) (Fig. 4d), and the percentage was higher
than those who reported scores equal to or greater than
normative values in each of these domains.
Correlation analysis
At week 24, reported PRO scores demonstrated moder-
ate to strong correlation with clinical measures of dis-
ease activity (DAS28 and CDAI) except for RE with the
CDAI (Fig. 5). There was also moderate to strong cor-
relation between PROs and individual SF-36 domains,
with the strongest correlation between domains that
measure similar constructs: the FACIT-F with VT (r =
0.76), HAQ-DI with PF (r = -0.63) and VAS pain with
BP (r = -0.72).
Discussion
In this phase III RCT, patients with moderate to severely
active RA, who were MTX-IR reported that treatment with
sarilumab +MTX resulted in improvements in pain, phys-
ical function, fatigue, and general health status that were
clinically meaningful and greater than with placebo +
MTX. These results complement the clinical efficacy previ-
ously reported [4].
There was concordance across PROs, with durable re-
sponses that appeared as early as 2 weeks in PtGA, pain,
physical function, and fatigue scores, which were sus-
tained through week 52. Improvements with 200 mg
were generally greater than with the 150 mg dose. The
FACIT-F scores showed significant and clinically mean-
ingful improvement with sarilumab treatment; fatigue
has a substantial impact in RA [19] and may be of
greater patient concern than other signs and symptoms
such as tender and swollen joints [20].
Fig. 3 Responder analyses for patients with improvement equal to or greater than the minimal clinically important difference (MCID). a Differences
from placebo in the percentage of patients reporting improvement equal to or greater than the MCID after 24 weeks of treatment according to
patient global assessment (PtGA), pain, functional assessment of chronic illness therapy-fatigue (FACIT-F), health assessment questionnaire-disability
index (HAQ-DI), and the Short Form 36 (SF-36) physical and mental component scores. b Differences from placebo in the percentage of patients
reporting improvements equal to or greater than the MCID after 24 weeks of treatment in SF-36 domain scores. PF physical functioning, RP role
physical, BP body pain, GH general health, VT vitality, SF social functioning, RE role emotional, MH mental health, NNT number needed to treat for
sarilumab +methotrexate (MTX) versus placebo +MTX
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Fig. 4 Responder analyses for normative scores and patient acceptable symptom state (PASS). a Percentage of patients reporting scores equal to
or greater than normative values on the functional assessment of chronic illness therapy-fatigue (FACIT-F) and Short Form 36 (SF-36) at baseline.
b Percentage of patients reporting scores equal to or greater than PASS thresholds at baseline. c Percentage of patients reporting scores equal to
or greater than normative values on the FACIT-F and SF-36 at week 24. d Percentage of patients reporting scores equal to or greater than PASS
thresholds at week 24. PF physical functioning, RP role physical, BP body pain, GH general health, VT vitality, SF social functioning, RE role emotional,
MH mental health
Fig. 5 Correlation between observed patient-reported outcomes and disease activity scores at Week 24
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Responder analyses demonstrated benefit using a var-
iety of approaches. In addition to reporting improve-
ments equal to or greater than the MCID in PtGA, pain,
HAQ-DI and FACIT-F scores that exceeded placebo,
the proportions of responders at 24 weeks were
greater across all PROs with both sarilumab doses
than placebo. These responses resulted in a NNT
ranging from 3.8 to 5.4 with sarilumab 200 mg,
indicating that few patients would need to be treated
to achieve clinically meaningful improvement. It is
worth noting that the responder analysis conducted
in this study was based on a conservative approach;
patients who discontinued or received rescue medica-
tion were considered non-responders rather than as
missing data.
As in other RCTs of biologic DMARDs [21–24], low
baseline SF-36 scores indicated substantial impairment
of general health status when compared with an age-
adjusted and gender-adjusted US normative population,
with significant improvements after treatment. Further-
more, using a higher level of response, i.e., improvement
equal to or greater than the normative values for SF-36
PCS and MCS (≥50) and SF-36 domains based on
this specific protocol population, were significant with
sarilumab versus placebo. The achievement of norma-
tive values is also a more meaningful response than
PASS, which represents a threshold of acceptability
rather than demonstrating parity with an age-matched
and gender-matched population, without arthritis or
comorbidities. Together, these data indicate that ac-
tive treatment with both doses of sarilumab improved
health status and fatigue to levels commensurate with
a patient population without arthritis or co-morbidities
typical in RA.
Indeed, while correlation between symptoms/disease
activity and functional outcomes suggested that clinical
effects translate into patient-reported improvement in
PtGA, pain, physical function and general health status,
many of the correlations between the observed scores
between PROs at week 24 were only moderate, indicat-
ing that these measures assess different domains of re-
sponse and reflect relief from the broad burden of
disease on patients’ lives.
A limitation of this study is that other than PtGA and
HAQ-DI, all PROs were generic and do not specifically
query about RA. However, all PROs utilized do assess
concepts relevant to patients with RA and have been
well-validated for use in RA. Additionally, the use of
hierarchical testing procedures limited the ability to
interpret some PRO data with regard to claims of
statistical significance. Generalizability of the NNT es-
timates may also be limited because the comparator
group, placebo +MTX, may not necessarily reflect
clinical practice.
Conclusions
In conclusion, reductions in disease activity with sarilu-
mab treatment are associated with patient-reported ben-
efits in global disease activity, pain, physical function,
fatigue, and general health status. These effects, reported
as early as week 2 and maintained over the 52-week trial
duration, provide evidence of long-term benefits.
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of the Research Cell of C.S.M. Medical University, Lucknow; Ethics Committee of
Care Institute of Medical Sciences CIMS Hospitals, Ahmedabad; Daegu Catholic
University Medical Center, Daegu-si; Ministry of Health Ethics Committee, Ankara;
Research Ethics Committee Faculty of Medicine Cairo University, Cairo; WIRB,
Olympia, WA; University of California, San Diego IRB, La Jolla, CA; University of
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